Skip to main content
STARPHARMA HOLDINGS LIMITED logo

STARPHARMA HOLDINGS LIMITED — Investor Relations & Filings

Ticker · SPL ISIN · AU000000SPL0 LEI · 254900WRGE3OUSWGMB55 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,316 across all filing types
Latest filing 2024-01-18 Investor Presentation
Country AU Australia
Listing ASX SPL

About STARPHARMA HOLDINGS LIMITED

https://starpharma.com/

Starpharma Holdings Limited is a biopharmaceutical company focused on the development of dendrimer technology for pharmaceutical and life science applications. The company utilizes its proprietary DEP® (Dendrimer Enhanced Product) delivery platform to improve the performance of existing drugs by enhancing solubility, reducing toxicity, and providing targeted delivery. Its clinical-stage internal pipeline includes DEP® docetaxel, DEP® cabazitaxel, and DEP® irinotecan, primarily targeting oncology. Starpharma also markets VivaGel® BV, a non-antibiotic treatment and prevention for bacterial vaginosis, and VIRALEZE™, an antiviral nasal spray containing astodrimer sodium. The company collaborates with global pharmaceutical firms to apply its dendrimer technology to various therapeutic areas, including antibody-drug conjugates and radiopharmaceuticals.

Recent filings

Filing Released Lang Actions
DEP cabazitaxel data presentation at ASCO GI cancer meeting 4 pages 1.8MB
Investor Presentation Classification · 95% confidence The document is a detailed announcement of clinical trial data presentation at a scientific conference (ASCO GI cancer meeting) regarding Starpharma's DEP cabazitaxel drug. It includes clinical trial results, efficacy and safety data, and commentary from medical professionals and company executives. The content focuses on scientific and clinical data presentation rather than financial results, regulatory filings, or corporate governance. It is not a full financial report, earnings release, or regulatory filing. The document is a presentation of clinical trial data at a medical conference, which aligns with the category of Investor Presentation (IP) as it provides detailed information on the company's product development, clinical progress, and potential market impact for investors and stakeholders. The length and detail support it being a presentation rather than a brief announcement or regulatory filing.
2024-01-18 English
Notification regarding unquoted securities - SPL 7 pages 30.9KB
Share Issue/Capital Change Classification · 95% confidence The document is a notification regarding the issue of unquoted equity securities under an employee incentive scheme by Starpharma Holdings Limited. It details the number and type of securities issued, dates, and mentions key management personnel involved. The content focuses on the issuance of securities, specifically performance rights, and includes references to ASX listing rules and employee incentive plans. There is no financial performance data, earnings information, or management discussion. The document is an announcement of a capital change related to securities issuance rather than a full report or regulatory filing. Therefore, it fits best under the category of Share Issue/Capital Change (SHA). The document length and detail support this classification with high confidence.
2024-01-11 English
Appendix 3X - Cheryl Maley 2 pages 243.6KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3X Initial Director’s Interest Notice' and references ASX listing rule 3.19A.1 and section 205G of the Corporations Act. It details the initial director's relevant interests in securities, including performance rights, and notes the director's appointment date. This is a report of personal share transactions or holdings by a company director, which fits the definition of 'Director's Dealing' filings. The document length is short and focused solely on director interests, with no financial results or other report content. Therefore, the correct classification is DIRS (Director's Dealing).
2024-01-11 English
Final Director's Interest Notice - J Fairley 2 pages 254.4KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Z Final Director’s Interest Notice' and references ASX listing rule 3.19A.3 and section 205G of the Corporations Act. It details the securities holdings and interests of a director who has ceased to be a director, including shares and performance rights. The document is short (2400 characters) and focuses on director shareholdings and interests, which aligns with insider trading or director dealings disclosures. There is no financial performance data, earnings information, or management discussion. Therefore, this document fits the category of Director's Dealing (DIRS).
2024-01-11 English
Notification of cessation of securities - SPL 4 pages 23.9KB
Regulatory Filings Classification · 95% confidence The document is a notification about the cessation (lapse) of certain securities (performance rights) issued by Starpharma Holdings Limited. It details the number of securities that have ceased, the reason for cessation, and the updated issued capital following these changes. There is no financial report, earnings data, or management discussion. The document is a regulatory announcement about changes in issued securities, specifically cessation of securities, which fits the category of Regulatory Filings (RNS) as it does not fall under more specific categories like Share Issue/Capital Change (SHA) or Transaction in Own Shares (POS) because it is about lapse of rights rather than issuance or buyback. The document length is short and it is a formal notification to the exchange about securities status changes.
2024-01-11 English
Application for quotation of securities - SPL 7 pages 29.6KB
Share Issue/Capital Change Classification · 100% confidence The document is an announcement from Starpharma Holdings Limited regarding the quotation of securities issued under an employee incentive scheme. It details the number and type of securities to be quoted, issue dates, and compliance with ASX Listing Rules. There is no financial data, management discussion, or report content. The document is a formal notification of a capital change related to employee share scheme securities being quoted on the exchange. This fits the definition of a Share Issue/Capital Change announcement rather than a full financial report or other filing type.
2023-12-20 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.